Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 10/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | TAS2R8 | Q9NYW2 | 2/20 | 0.37 |
| ▸ | IGF1R | P08069 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1208069 | 0.85 | AR (0.52) | ARCNR1 | |
| SCHEMBL1208140 | 0.85 | AR (0.53) | ARCNR1 | |
| SCHEMBL1207996 | 0.85 | TAS2R8 (0.35) | TAS2R8IGF1R | |
| SCHEMBL3528150 | 0.85 | AR (0.56) | ARCNR1 | |
| SCHEMBL1208696 | 0.84 | AR (0.51) | ARCNR1 | |
| SCHEMBL1208731 | 0.83 | AR (0.49) | ARCNR1 | |
| SCHEMBL3529259 | 0.82 | AR (0.55) | ARCNR1TAS2R8IGF1R | |
| SCHEMBL3525124 | 0.81 | AR (0.54) | ARCNR1IGF1R | |
| SCHEMBL3985805 | 0.81 | AR (0.54) | ARCNR1IGF1R | |
| SCHEMBL3527116 | 0.81 | AR (0.54) | ARCNR1TAS2R8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046105-A1 | Heterocycle-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising them and use thereof | SANOFI-AVENTIS (FR) | 2011-02-24 | — | — | US | disclosed |
| US-20110046105-A1 | Heterocycle-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising them and use thereof | SANOFI-AVENTIS (FR) | 2011-02-24 | — | — | US | disclosed |
| EP-2242746-A1 | HETEROCYCLICALLY-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | Sanofi-Aventis (FR) | 2010-10-27 | — | — | EP | disclosed |
| WO-2009098000-A1 | HETEROCYCLICALLY-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046105-A1 | Heterocycle-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising them and use thereof | GIPR, DDC, PGC | AR 1832/4885CNR1 660/4885TAS2R8 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.